KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring ...
Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...
This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL ...
Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)–positive adult B-ALL in 2018, ...
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...
Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...
NEWS AT SIX. THERE IS NEW HOPE FOR CHILDREN AND ADULTS WITH LEUKEMIA, A LIFE SAVING DRUG IS CHANGING THE GAME FOR TREATING THE DISEASE. AND A KCCI INVESTIGATES REPORT. LAURA TERRELL LEARNED DOCTORS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results